Zhu AX, Kang Y-K, Yen C-J, et al. REACH-2: A randomized, double-blind, placebo-controlled phase III study of ramucirumab (Cyramza) versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol 36, 2018 (suppl; abstr 4003).
Argininedeprivatie bij ASS1-deficient maligne pleuraal mesothelioom
jan 2017 | Mesothelioom